| Ytd | -7.69% | |
| 1y | 7.14% |
| Open | 2.38 | Prev Close | 2.38 | Low | 2.37 | High | 2.40 | Mkt Cap | 25.76M |
| Vol | 15.18K | Avg Vol | 34.58K | EPS | -1.92 | P/E | -1.25 | Forward P/E | 3.57 |
| Beta | 0.25 | Short Ratio | 10.45 | Inst. Own | 34.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 2.20 | 200-d Avg | 2.37 | 1yr Est | 8.00 |
AYTU News
ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001385818/000143774926021707/aytu20260624c_8k.htm
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raise
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Conse
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have received a consensus rating of "
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consen
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch i
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Na
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have been assigned a consensus recomm
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Na
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Na
DENVER, CO / ACCESS Newswire / January 12, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Na
Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) has been given a consensus recommendation of "H
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earni
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
Friday's session saw 100 companies set new 52-week lows.
On Thursday, 498 companies reached new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Companies Reporting Before The Bell • WESCO International (NYSE:WCC) is projected to report quarter
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
On Friday morning, 446 companies hit new 52-week lows.
On Monday, 429 stocks made new 52-week lows.
On Thursday, 529 companies set new 52-week lows.
On Tuesday, 250 stocks hit new 52-week lows.